Radiation-based immunogenic vaccine combined with a macrophage “checkpoint inhibitor” for boosting innate and adaptive immunity against metastatic colon cancers

 

This new article publication from Acta Pharmaceutica Sinica B, discusses how the use of a radiation-based immunogenic vaccine combined with a macrophage “checkpoint inhibitor” can boost innate and adaptive immunity against metastatic colon cancers.

 

Immunogenic dying tumor cells hold promising prospects as cancer vaccines to activate systemic immunity against both primary and metastatic tumors. Especially, X-ray- induced dying tumor cells are rich in highly immunogenic tumor-associated antigens and self-generated dsDNA as potent adjuvants.

 

The authors of this article note that the X-ray induction process can result in the excessive exposure of phosphatidylserine in cancer vaccines, which can specifically bind with the MerTK receptor on macrophages, acting as a “checkpoint” to facilitate immune silence in the tumor microenvironment.

 

Therefore, a novel strategy was developed combining X-ray-induced cancer vaccines with UNC2250, a macrophage MerTK “checkpoint inhibitor,” for treating peritoneal carcinomatosis in colon cancer. By incorporating UNC2250 into the treatment regimen, immunosuppressive efferocytosis of macrophages, which relies on MerTK-directed recognition of phosphatidylserine on vaccines, was effectively blocked. Consequently, the immune analysis revealed that this combination strategy promoted the maturation of dendritic cells and M1-like repolarization of macrophages, thereby simultaneously eliciting robust adaptive and innate immunity.

 

This innovative approach utilizing X-ray-induced vaccines combined with a checkpoint inhibitor may provide valuable insights for developing effective cancer vaccines and immunotherapies targeting colon cancer.

Graphical Abstract: available at   

Frozen dying tumor cells (FDT) combined with efferocytosis inhibitors can mobilize dendritc cells and macrophages simultaneously, thereby eliciting robust innate and adaptive immunity against peritoneal carcinomatosis in colon cancer.

# # # # # #

The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.

For more information please visit

Editorial Board: editorial-board

 

APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).

 

Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).

 

CiteScore: 19.4

Impact Factor: 14.5

JIF without self-citation: 13.7

ISSN 2211-3835

 # # # # #

Hongbo Xu, Xianya Qin, Yuanyuan Guo, Siyu Zhao, Xingxing Feng, Runzan Zhang, Tianyi Tian, Li Kong, Conglian Yang, Zhiping Zhang, Radiation-based immunogenic vaccine combined with a macrophage “checkpoint inhibitor” for boosting innate and adaptive immunity against metastatic colon cancers, Acta Pharmaceutica Sinica B, Volume 14, Issue 5, 2024, Pages 2247-2262, ISSN 2211-3835,

---

---